当前位置:
首页>产品中心>单抗/多抗>Cergutuzumab ELISA Kit|Cergutuzumab ELISA试剂盒(靶标:)
Cergutuzumab ELISA Kit|Cergutuzumab ELISA试剂盒(靶标:)
- 货号:RB9TDY546018
- 价格:面议
- 点击:269
产品介绍
产品参数
| 应用 | ELISA |
|---|
| 检测方法 | Colorimetric |
|---|
| 灵敏度 | 0.156 μg/ml |
|---|
| 检测范围 | 0.31-5 μg/mL |
|---|
| 回收率 | 80-120% |
|---|
| 样本类型 | Plasma, Serum |
|---|
| 检测类型 | Quantitative |
|---|
| 稳定性和储存 | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
|---|
| 运输条件 | 2-8 ℃ |
|---|
| 登录号 | P06731 |
|---|
| 背景信息 | cergutuzumab amunaleukin (CEA-IL2v, RG7813), a novel monomeric CEA-targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent carcinoembryonic antigen (CEA)-specific antibody devoid of Fc-mediated effector functions. Its molecular design aims to (i) avoid preferential activation of regulatory T-cells vs. immune effector cells by removing CD25 binding; (ii) increase the therapeutic index of IL-2 therapy by (a) preferential retention at the tumor by having a lower dissociation rate from CEA-expressing cancer cells vs. IL-2R-expressing cells, (b) avoiding any FcγR-binding and Fc effector functions and (c) reduced binding to endothelial cells expressing CD25; and (iii) improve the pharmacokinetics, and thus convenience of administration, of IL-2. |
|---|
| 别名 | CEA-IL-2v, RG7813, RO-6895882, 1509916-03-3 |
|---|
| 备注 | For Research Use Only. |
|---|
【仅供科学研究使用】
相关产品: